Britain defends AstraZeneca vaccine after it’s called ‘quasi-ineffective’ by French President


Article content

Britain’s health minister on Wednesday defended the country’s vaccine roll-out strategy after skepticism emerged in Europe, saying the science supported a decision to give the shot developed by Oxford University and AstraZeneca to all age groups.

France, Belgium and Germany are among the European Union countries to recommend that Oxford’s vaccine is only given to under 65s, while French President Emmanuel Macron was quoted on Friday as saying that the shot appeared “quasi-ineffective” among those over 65.

That is strongly disputed by the vaccine’s developers and the British government, and health minister Matt Hancock defended Britain’s approach when asked about Macron’s comment.

“My view is that we should listen to the scientists … and the science on this one was already pretty clear, and then with this publication overnight is absolutely crystal clear that the Oxford vaccine not only works but works well,” health secretary Matt Hancock told BBC Radio, referring to new data from Oxford.

That preprint study showed that the Oxford vaccine had 76% efficacy after a first shot in the 3 months until a second shot was given, and higher efficacy if the second dose was given at least 12 weeks after the first, supporting Britain’s decision to extend the gap between doses.

More On This Topic

However, the study did not give extra direct evidence of efficacy in older people.

Asked about Macron’s comment, Oxford Vaccine Group chief Andrew Pollard said: “I don’t understand what that statement means.”

“The point is that we have rather less data in older adults, which is why people have less certainty about the level of protection,” Pollard told BBC radio.

“But we have good immune responses in older adults very similar to younger adults, the protection that we do see is in exactly the same direction, and of a similar magnitude.”



Source link